Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Berlau

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Expert Opinion on Drug Safety|August 17, 2024
Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety reviewEszter Czifrus, Daniel J Berlau
Expert Review of Neurotherapeutics|August 12, 2023
Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapyEszter Czifrus, Daniel J Berlau
Learning & Memory (Cold Spring Harbor, N.Y.)|December 6, 2003
Basolateral amygdala lesions do not prevent memory of context-footshock trainingDaniel J Berlau, James L McGaugh
Neurobiology of Learning and Memory|February 7, 2006
Enhancement of extinction memory consolidation: the role of the noradrenergic and GABAergic systems within the basolateral amygdalaDaniel J Berlau, James L McGaugh
Expert Opinion on Pharmacotherapy|March 6, 2020
New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeuticsSharon M Grages, Michael Bell, Daniel J Berlau
Expert Opinion on Pharmacotherapy|March 30, 2026
Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an updateLeyken Wilson, Lucy M Johnson, Daniel J Berlau
Pharmacotherapy|February 3, 2017
Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging PharmacotherapiesAndrea M Reinig, Sara Mirzaei, Daniel J Berlau
International Journal of Geriatric Psychiatry|March 5, 2009
The prevalence of disability in the oldest-old is high and continues to increase with age: findings from The 90+ StudyDaniel J Berlau, María M Corrada, Claudia Kawas
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 8, 2022
A case for continuing statin medications in the intensive care unit: Reducing the risk for deliriumKyra L Navia, Bridget K Anthony, Daniel J Berlau
Pain Management|February 9, 2026
Ketamine for acute and chronic pain: beyond anaesthesiaHao G Duong, Tariq G Pulskamp, Daniel J Berlau
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Expert Opinion on Drug Safety|August 17, 2024
Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety reviewEszter Czifrus, Daniel J Berlau
Expert Review of Neurotherapeutics|August 12, 2023
Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapyEszter Czifrus, Daniel J Berlau
Learning & Memory (Cold Spring Harbor, N.Y.)|December 6, 2003
Basolateral amygdala lesions do not prevent memory of context-footshock trainingDaniel J Berlau, James L McGaugh
Neurobiology of Learning and Memory|February 7, 2006
Enhancement of extinction memory consolidation: the role of the noradrenergic and GABAergic systems within the basolateral amygdalaDaniel J Berlau, James L McGaugh
Expert Opinion on Pharmacotherapy|March 6, 2020
New and emerging pharmacotherapy for duchenne muscular dystrophy: a focus on synthetic therapeuticsSharon M Grages, Michael Bell, Daniel J Berlau
Expert Opinion on Pharmacotherapy|March 30, 2026
Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an updateLeyken Wilson, Lucy M Johnson, Daniel J Berlau
Pharmacotherapy|February 3, 2017
Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging PharmacotherapiesAndrea M Reinig, Sara Mirzaei, Daniel J Berlau
International Journal of Geriatric Psychiatry|March 5, 2009
The prevalence of disability in the oldest-old is high and continues to increase with age: findings from The 90+ StudyDaniel J Berlau, María M Corrada, Claudia Kawas
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 8, 2022
A case for continuing statin medications in the intensive care unit: Reducing the risk for deliriumKyra L Navia, Bridget K Anthony, Daniel J Berlau
Pain Management|February 9, 2026
Ketamine for acute and chronic pain: beyond anaesthesiaHao G Duong, Tariq G Pulskamp, Daniel J Berlau
Pageof 4